Qiagen (NYSE:QGEN – Get Free Report) and Parallax Health Sciences (OTCMKTS:PRLX – Get Free Report) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, profitability, risk, valuation, earnings and analyst recommendations.
Profitability
This table compares Qiagen and Parallax Health Sciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Qiagen | 19.49% | 14.24% | 8.23% |
| Parallax Health Sciences | N/A | N/A | N/A |
Earnings and Valuation
This table compares Qiagen and Parallax Health Sciences”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Qiagen | $2.09 billion | 4.29 | $424.88 million | $1.95 | 22.34 |
| Parallax Health Sciences | N/A | N/A | N/A | N/A | N/A |
Qiagen has higher revenue and earnings than Parallax Health Sciences.
Analyst Recommendations
This is a summary of recent ratings for Qiagen and Parallax Health Sciences, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Qiagen | 1 | 8 | 4 | 1 | 2.36 |
| Parallax Health Sciences | 0 | 0 | 0 | 0 | 0.00 |
Qiagen currently has a consensus price target of $43.93, indicating a potential upside of 0.84%. Given Qiagen’s stronger consensus rating and higher possible upside, analysts clearly believe Qiagen is more favorable than Parallax Health Sciences.
Insider and Institutional Ownership
70.0% of Qiagen shares are owned by institutional investors. 9.0% of Qiagen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Summary
Qiagen beats Parallax Health Sciences on 10 of the 10 factors compared between the two stocks.
About Qiagen
QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands.
About Parallax Health Sciences
Parallax Health Sciences, Inc. is an integrated digital healthcare company. It is engaged in the provision of personalized patient care through remote healthcare services, behavioral health systems, and Point-of-Care diagnostic testing. The firm operates through the following segments: Remote Patient Monitoring, Behavioral Health Systems, and Corporate. The Remote Patient Monitoring segment offers a technology platform that includes a complete remote patient care delivery system through PHM. The Behavioral Health Systems segment includes the intellectual property, Reliable Evidence-Based Outcomes Optimization Technologies, through its wholly-owned subsidiary, Parallax Behavioral Health, Inc. The Corporate segment consists of management and administrative services. The company was founded on July 6, 2005 and is headquartered in Los Angeles, CA.
Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.
